The user is expressing an obsession with hair loss and spends all their time researching and discussing it. Other users suggest seeking therapy and focusing on other aspects of life.
The conversation humorously discusses hair loss treatments, including finasteride, minoxidil, and dermarolling, with users sharing personal experiences and side effects. Some users mention changes in hair and semen consistency, while others discuss male contraception methods.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.
Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.
Bald men in Mozambique are being targeted due to superstitions that their heads contain gold, leading to dangerous rituals. The conversation humorously discusses this belief and its implications.
The conversation humorously discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. The user jokes about the obvious signs of balding.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
People are discussing hair loss treatments, including finasteride, minoxidil, and dutasteride, focusing on maintenance and potential regrowth. Some users joke about unrealistic expectations, while others share experiences and advice on treatment options.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
Hair loss affects mental health and self-esteem, causing anxiety and depression. Treatments like finasteride, minoxidil, and hair transplants help some, but others continue to struggle.
Balding can make dating more challenging, especially with superficial attitudes, but confidence and fitness can help. Some embrace shaving their heads, while others focus on self-improvement and acceptance.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.
A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.
Transgender hormone therapy, including Estradiol Valerate, Spironolactone, and Progesterone Micronized, can reverse male pattern baldness and improve hair health. The user shares their positive experience with hair regrowth after transitioning from male to female.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.